432 completed. 432 Phase 1, 2 Phase 2.
By phase and status
Follow Healthy Volunteer: new trials by email Literature Review of Healthy Volunteer trials Research Report on Healthy Volunteer
Trials (filtered) newest first · largest first
All 432 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants Efgartigimod PH20 SC via PFS, Efgartigimod PH20 SC via AI - Healthy Volunteer, Healthy Adult Participants Phase 1 Completed 32 2026-06-19 2026-10-14 A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants Bretisilocin - Healthy Volunteer Phase 1 Completed 26 2026-05-26 2026-09-30 A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants AN01, Placebo - Healthy Volunteer, Healthy Participants Study Phase 1 Completed 25 2026-05-13 2026-08-17 A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants ABBV-932 - Healthy Volunteer Phase 1 Completed 8 2026-05-04 2026-10-13 A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants Nacresertib, Placebo for Nacresertib - Healthy Volunteer Phase 1 Completed 12 2026-04-21 2026-07-20 A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants Ethinyl Estradiol + Levonorgestrel, ABBV-722 - Healthy Volunteer Phase 1 Completed 15 2026-03-27 2026-07-30 A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants ABBV-722, Upadacitinib - Healthy Volunteer Phase 1 Completed 16 2026-02-26 2026-08-04 A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives ABBV-295, Levonorgestrel/Ethinyl Estradiol - Healthy Volunteer Phase 1 Completed 20 2026-02-11 2026-08-31 A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers ABBV-8736 - Healthy Volunteer Phase 1 Completed 40 2026-02-11 2026-07-20 A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 Omaveloxolone - Healthy Volunteer Phase 1 Completed 70 2025-12-12 2026-05-14 A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C) - Healthy Volunteer Phase 1 Completed 64 2025-11-24 2026-05-04 A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants ABBV-1042, Placebo - Healthy Volunteer Phase 1 Completed 36 2025-10-27 2026-10-15 A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants ABBV-1354 - Healthy Volunteer Phase 1 Completed 8 2025-10-15 2026-01-05 Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants atirmociclib (PF-07220060) - Healthy Volunteer Phase 1 Completed 72 2025-10-08 2026-08-21 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects. PN-881 Oral Solution, PN-881 Oral Tablet, Placebo - Healthy Volunteer Phase 1 Completed 146 2025-10-07 2026-08-05 A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg, Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg - Fed Conditions, Healthy Volunteer Phase 1 Completed 50 2025-09-29 2026-01-12 Food Effect Study in Healthy Volunteers Icovamenib, Icovamenib HPMC - Healthy Volunteer Phase 1 Completed 60 2025-09-11 2026-02-11 A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55 Omaveloxolone, Omeprazole - Healthy Volunteer Phase 1 Completed 22 2025-09-02 2025-10-23 A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers ABBV-8736, Placebo - Healthy Volunteer Phase 1 Completed 24 2025-09-02 2026-04-28 Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants ABBV-932, Placebo for ABBV-932 - Healthy Volunteer Phase 1 Completed 20 2025-08-21 2025-12-31
Showing 20 of 432. Sign in to see all of them.
Narrower conditions Renal Insufficiency (4) · Dermatitis, Atopic (2) · Hidradenitis Suppurativa (2) · Neoplasms (2) · Urinary Bladder, Overactive (2) · Urinary Incontinence (2) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Behavioral Symptoms (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiovascular Diseases (1) · Chronic Pain (1) · Colitis, Ulcerative (1) · Coronavirus Infections (1)
Broader conditions Infections (9) · Urogenital Diseases (8) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (7) · Nervous System Diseases (7) · Urologic Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Pathological Conditions, Signs and Symptoms (6) · Central Nervous System Diseases (5) · Genetic Diseases, Inborn (5) · Kidney Diseases (5) · Mental Disorders (5) · RNA Virus Infections (5) · Respiratory Tract Diseases (5)
Interventions Ritonavir (20) · danoprevir (15) · Itraconazole (12) · Moxifloxacin (12) · Midazolam (10) · 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (7) · Rabeprazole (7) · Rifampin (7) · aleglitazar (7) · Ketoconazole (5) · dolutegravir (5) · 4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propylcinnoline-3-carboxamide (4) · Digoxin (4) · Metformin (4) · Rosuvastatin Calcium (4)
Sponsors Hoffmann-La Roche (107) · Genentech, Inc. (33) · AbbVie (28) · Biogen (21) · AstraZeneca (20) · Celgene (12) · Pfizer (11) · Astellas Pharma Inc (6) · GlaxoSmithKline (6) · Regeneron Pharmaceuticals (5) · Yuhan Corporation (5) · Amgen (4) · Genzyme, a Sanofi Company (4) · Immunome, Inc. (4) · Supernus Pharmaceuticals, Inc. (4)
Countries United States (225) · United Kingdom (39) · China (27) · Netherlands (26) · France (23) · Japan (17) · Canada (14) · South Korea (12) · Germany (9) · New Zealand (9) · Australia (8) · Belgium (7) · Russia (3) · Singapore (3) · Sweden (3)
Top investigators Leon Carayannopoulos, MD (4) · Scott Holden, M.D. (3)
Results publications PMID 27381392 , PMID 30091852 , PMID 37563858 , PMID 37705327 , PMID 41058119 , PMID 42133202 , PMID 18190252 , PMID 19419343 , PMID 22500821 , PMID 22980315 , PMID 23712757 , PMID 24057039 , PMID 24627419 , PMID 24998012 , PMID 25289522 , PMID 25724156 , PMID 26055360 , PMID 26312582 , PMID 26363899 , PMID 26691837 , PMID 27154174 , PMID 27368672 , PMID 28559255 , PMID 28769925 , PMID 29178442 , PMID 29909549 , PMID 30305980 , PMID 30910894 , PMID 30957581 , PMID 31043095 , PMID 31303281 , PMID 31604104 , PMID 31883703 , PMID 32105576 , PMID 32274653 , PMID 32337660 , PMID 32851809 , PMID 32857315 , PMID 33325799 , PMID 33488576 , PMID 33529172 , PMID 33778928 , PMID 33813736 , PMID 34145168 , PMID 34176392 , PMID 35644931 , PMID 35691544 , PMID 35982464 , PMID 36871246 , PMID 37442656
NIH funding 2014 (10) , 2015 (6) , 2017 (6) , 2018 (4) , 2019 (3) , 2008 (1) , 2009 (1) , UG3DA050308 (1)